Please login to the form below

Not currently logged in

Bodnar pleads guilty in BMS case

Andrew Bodnar, former senior executive of Bristol-Myers Squibb, has pleaded guilty to dishonest dealings relating to a patent deal involving Plavix

Andrew Bodnar, former senior executive of Bristol-Myers Squibb (BMS), has pleaded guilty to dishonest dealings relating to a patent deal involving Plavix. 

In 2006, BMS was negotiating a settlement of litigation with Apotex over the validity of the patent for Plavix. At the time, BMS was subject to a consent decree – for an unrelated matter – requiring the company to submit any proposed patent settlements for review with the Federal Trade Commission (FTC).  

Bodnar reassured Apotex that BMS would not launch a generic version of Plavix if the generics company agreed not to launch a version until 2011. He misled the FTC by claiming that he had not made these representations.

In June 2007, BMS agreed to plead guilty and pay a $1m fine. The US Department of Justice said that BMS had tried to block competition that could have lowered the cost of blood-thinning drugs. 

Scot Hammond, Acting Assistant Attorney General in charge of the Department's anti-trust division said: "Those who attempt to mislead the federal government or undermine the integrity of its functions should expect to face criminal prosecution."

Bodnar could face a year in jail and a fine of up to $100,000 or double the amount of any financial gain derived from his illegal actions.

7th April 2009


COVID-19 Updates and Daily News

Featured jobs


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....